What is Avectas?
Avectas operates as a specialized cell engineering technology firm, primarily focused on optimizing the manufacturing processes and cost-effectiveness of cellular therapies. The company's flagship innovation, Solupore, serves as a transformative tool that integrates multiple unit processes into a single, streamlined consumable. This technological advancement is designed to mitigate common industry challenges, such as high facility overheads and frequent batch failures, which have historically hindered the widespread adoption of autologous cell therapies. By targeting the biopharmaceutical sector, Avectas provides a critical bridge between laboratory-scale research and commercial-scale production, specifically enhancing the accessibility and efficacy of CAR T-cell treatments for patients globally.
How much funding has Avectas raised?
Avectas has raised a total of $32.5M across 3 funding rounds:
Series A
$2.5M
Series B
$10M
Series C
$20M
Series A (2018): $2.5M with participation from Horizon Global
Series B (2019): $10M led by Seamus Mulligans
Series C (2020): $20M supported by Seamus Mulligan
Key Investors in Avectas
Horizon Global
A global investment firm focused on long-term value creation and strategic growth in the industrial and technology sectors.
Seamus Mulligans
A private investment entity with a specialized interest in high-growth biotechnology and medical device innovation.
Seamus Mulligan
An individual investor providing strategic capital to support the advancement of next-generation cellular therapy manufacturing.
What's next for Avectas?
With the recent influx of capital, Avectas is positioned to scale its operations significantly, focusing on the commercial expansion of the Solupore platform. The strategic roadmap involves deepening partnerships within the biopharmaceutical industry to integrate its technology into existing manufacturing workflows. By prioritizing operational efficiency and cost reduction, the company aims to lower the barrier to entry for advanced therapies, ultimately driving broader clinical adoption. Future efforts will likely center on expanding the manufacturing capacity to meet the growing demand for scalable cell therapy solutions, ensuring that the company remains a pivotal player in the evolution of personalized medicine.
See full Avectas company page
